Stabilized human immunodeficiency virus (HIV) clade C envelope (Env) trimer vaccines and methods of using same
US-10716845-B2 · Jul 21, 2020 · US
env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site · Cooperative Patent Classification (CPC)
Chemical and metallurgical processes, compounds, and materials.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | C07K14/162 |
| Official title | {env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site} |
| Display label | env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site |
| Total patents | 157 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is rapidly declining.
| Year | Patents |
|---|---|
| 2015 | 6 |
| 2016 | 10 |
| 2017 | 5 |
| 2018 | 16 |
| 2019 | 19 |
| 2020 | 15 |
| 2021 | 30 |
| 2022 | 14 |
| 2023 | 12 |
| 2024 | 19 |
| 2025 | 10 |
| 2026 | 1 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Rapid elicitation of broadly neutralizing antibodies to hiv env
US-2020165324-A1 · May 28, 2020 · US
HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations
US-10647748-B2 · May 12, 2020 · US
Hiv-1 incidence biomarkers
US-2020095646-A1 · Mar 26, 2020 · US
V1/V2 fragments of a HIV-1 envelope glycoprotein
US-10507239-B2 · Dec 17, 2019 · US
D-peptide inhibitors of HIV entry and methods of use
US-10487121-B2 · Nov 26, 2019 · US
Anti-herv-k envelope antibody and uses thereof
US-2019345232-A1 · Nov 14, 2019 · US
Production of soluble hiv envelope trimers in planta
US-2019337994-A1 · Nov 7, 2019 · US
Hiv vaccination compositions
US-2019328864-A1 · Oct 31, 2019 · US
Compositions and Vaccine Combinations Containing Synthetic Human Immunodeficiency Virus (HIV) Envelope Antigen, and Methods of Use Thereof
US-2019321462-A1 · Oct 24, 2019 · US
Synthetic human immunodeficiency virus (HIV) envelope antigen, vectors, and compositions thereof
US-10369214-B2 · Aug 6, 2019 · US
Methods for safe induction of cross-clade immunity against hiv infection in humans
US-2019231866-A1 · Aug 1, 2019 · US
Compositions and methods for treating hiv/aids with immunotherapy
US-2019202895-A1 · Jul 4, 2019 · US
Broadly cross-reactive hiv-1-specific antibodies for prevention and treatment of hiv
US-2019185549-A1 · Jun 20, 2019 · US
Mosaic conserved region hiv immunogenic polypeptides
US-2019151440-A1 · May 23, 2019 · US
Cyclic HIV-1 Env V3 glycopeptide immunogens
US-10286057-B2 · May 14, 2019 · US
Broadly cross-reactive HIV-1 Env-specific antibodies
US-10280213-B2 · May 7, 2019 · US
Novel Scaffolded HIV-1 Vaccine Immunogens
US-2019125890-A1 · May 2, 2019 · US
Recombinant hcmv and rhcmv vectors and uses thereof
US-2019099479-A1 · Apr 4, 2019 · US
Immunogenic trimers
US-2019085033-A1 · Mar 21, 2019 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC C07K14/162?
- CPC C07K14/162 is the Cooperative Patent Classification code for “env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site.”
- How many patents are filed under CPC C07K14/162 (env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site)?
- Our database includes 157 publications tagged with this CPC code.
- Is patent activity under CPC C07K14/162 growing?
- Publication counts under this code: 19 in 2024 vs 10 in 2025 (latest complete years).